Slide 1: Fourth Quarter 2023 Earnings
Fourth Quarter 2023 Earnings February 1, 2024
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Launched a new integrated Revenue upside was broad E-Commerce platform in based in a challenging Launched EONIS-Q to help U.S. market environment automate SMA and SCID testing in newborns Advancing additional Strong expense operational initiatives
Slide 4: 4Q23 Revenue Highlights
4Q23 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -DD +LSD +LSD $0.7 B -HSD -HSD $0.7 B $0.7 B +LSD -LSD 4 Revenue performance provided on a non-COVID organic basis Reconciliations to the most directly comparable GAAP measure f
Slide 5: 2023 Revenue Highlights
2023 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -LSD +MSD +MSD $2.75 B -LSD -LSD $2.75 B $2.75 B +MSD +MSD 5 Revenue performance provided on a non-COVID organic basis Reconciliations to the most directly comparable GAAP measu
Slide 6: 4Q23 Financial Results
4Q23 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $696M 27.5% $1.25 $196M -6% y/y -480bps y/y -11% y/y +94% y/y Includes $7M of AES Organic: Adj. Gross Margin: Adj. Tax Rate: related inflows -7% | M&A: 0% | FX: 1% 60.2% | -360bps y/y 12.2% Non-COVID: Adj. Net Int
Slide 7: 2023 Financial Results
2023 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $2,751M 28.0% $4.65 $198M -17% y/y -860bps y/y -33% y/y -66% y/y Includes $203M of AES Organic: Adj. Gross Margin: Adj. Tax Rate: related outflows -16% | M&A: 0% | FX: 0% 61.5% | -440bps y/y 18.6% Non-COVID: Adj.
Slide 8: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE -9% Organic Growth 36.9% -DD -500bps y/y Reported: -8% | M&A: 0% | FX: 1% $320 M • -DD decline from Pharma/Biotech 4Q23 revenue +LSD -DD • +HSD growth from Academic/Gov’t • Software+ DD decline due to contract renewal - H
Slide 9: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS -6% Organic Growth 21.1% Reported: -4% | M&A: 0% | FX: 1% -760 bps y/y -LSD Non-COVID Organic Growth: 3% +DD $376 M 4Q23 revenue • +Mid-teens ImmunoDX globally, China ImmunoDX +HSD -DD • Reproductive Heal
Slide 10: 2024 Financial Guidance
2024 Financial Guidance ADJ. REVENUE $2.79B - 2.85B 2% to 4% reported Organic: 1% to 3% FX: 1%, M&A: 0% ADJUSTED OP. MARGIN ~28% ADJUSTED EPS $4.55 - $4.75 Adj. Net interest expense, other: ~$70M Adjusted tax rate: ~20% Average diluted share count: 123.5M 10
Slide 11: Revvity.com
Revvity.com